BioDrugs

, Volume 16, Issue 3, pp 220–222 | Cite as

Exendin 4

AC 2993, AC 2993 LAR
Adis R&D Profile

References

  1. 1.
    Parkes DG, Young AA, Petrella E, et al. Pharmacokinetics of exendin-4 in the rat following intravenous, subcutaneous and intraperitoneal administration. 81st Annual Meeting Endocrine Society; 1999 Jun 12; San Diego, 216-7Google Scholar
  2. 2.
    Kolterman O, Young G, Parker J, et al. Stimulation of endogenous insulin secretion by subcutaneous AC2993 (synthetic exendin-4) in healthy overnight fasted volunteers. Diabetes 1999 May; 48Suppl. 1: 199Google Scholar
  3. 3.
    Amylin Pharmaceuticals Inc. Amylin Pharmaceuticals reports successful study of second diabetes drug candidate AC2993 (synthetic exendin-4) in type 2 diabetes [media release 1999 Apr 30]. Available from URL: http://www.amylin.com [Accessed 2002 Jul 2]
  4. 4.
    Eng J, Friedrich I. Exendin family — agonist and antagonist of GLP-1 receptor. 15th International Diabetes Federation Congress; 1994 Nov 6–11; Kobe, 22Google Scholar
  5. 5.
    Gedulin R, Jodka C, Hoyt JA, et al. Exendin-4 decreases hemoglobin A(1c) in diabetic fatty Zucker rats. Diabetes 1998 May; 47Suppl. 1: 280Google Scholar
  6. 6.
    Edwards CMB, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose in healthy volunteers. Diabetic Med 2000 Mar; 17Suppl. 1: 69Google Scholar
  7. 7.
    Amylin Pharmaceuticals Inc. Amylin Pharmaceuticals reports positive phase 2 study of AC2993 (synthetic exendin-4) in people with type 2 diabetes [media release 1999 Oct 28]. Available from URL: http://www.amylin.com [Accessed 2002 Jul 2]
  8. 8.
    Amylin Pharmaceuticals Inc. Amylin Pharmaceuticals announces results from a new dose-finding phase 2 study of AC2993 (synthetic exendin-4) [media release 2000 Jan 7]. Available from URL: http://www.amylin.com [Accessed 2002 Jul 2]
  9. 9.
    Amylin Pharmaceuticals Inc. Amylin Pharmaceuticals announces cardiovascular risk factor reduced by AC2993 (synthetic exendin-4) [media release2000 Jan 10]. Available from URL: http://www.amylin.com [Accessed 2002 Jul 2]
  10. 10.
    Maksoud H, Barrow BA, Manley SE, et al. Subcutanous exendin-4 improves 24 hour glucose exposure in type 2 diabetes. Diabetes Res Clin Pract 2000 Sep; 50Suppl. 1:40Google Scholar
  11. 11.
    Bhavsar SP, Watkins JJ, Young AA. Central and peripheral administration of exendin-4 reduces food intake in rats. Diabetologia 1998 Aug;41Suppl. 1: 214Google Scholar
  12. 12.
    Brynes AE, Edwards CMB, Stanley SA, et al. Exendin-4 reduces energy intake at a free choice buffet meal in healthy volunteers. Diabetic Med 2000 Mar; 17Suppl. 1: 69Google Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations